CPIX - Cumberland Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
7.21
-0.02 (-0.28%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close7.23
Open7.27
Bid0.00 x 0
Ask0.00 x 0
Day's Range7.05 - 7.28
52 Week Range4.60 - 7.49
Volume3,072
Avg. Volume13,304
Market Cap114.61M
Beta0.49
PE Ratio (TTM)-16.39
EPS (TTM)-0.44
Earnings DateOct 30, 2017 - Nov 3, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
Trade prices are not sourced from all markets
  • Capital Cube9 days ago

    ETFs with exposure to Cumberland Pharmaceuticals, Inc. : October 9, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cumberland Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to CPIX-US. Comparing the performance and risk of Cumberland Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Cumberland Pharmaceuticals, Inc. :CPIX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
    Capital Cube12 days ago

    Cumberland Pharmaceuticals, Inc. :CPIX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017

    Categories: Yahoo FinanceGet free summary analysis Cumberland Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 8.67 million, Net Earnings of USD -5.16 million. Gross margins narrowed from 76.47% to 73.21% compared to the same period last year, operating (EBITDA) margins now -11.86% from 6.53%. Change in operating ... Read more (Read more...)

  • PR Newswire23 days ago

    Cumberland Pharmaceuticals Launches Promotion of Totect® in The U.S. for Emergency Oncology Intervention

    NASHVILLE, Tenn. and BURTON ON TRENT, England, Sept. 25, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX, 'Cumberland') and Clinigen Group plc (AIM:CLIN, 'Clinigen'), announced today the promotional launch of Totect® (dexrazoxane hydrochloride), in the U.S. Totect is an FDA-approved hospital based emergency oncology intervention drug, indicated to treat the toxic effects of anthracycline chemotherapy in case of extravasation. Extravasation occurs when an injected medicine escapes from the blood vessels and circulates into surrounding tissues in the body, causing severe damage and serious complications.

  • What Are The Drivers Of Cumberland Pharmaceuticals Inc’s (CPIX) Risks?
    Simply Wall St.last month

    What Are The Drivers Of Cumberland Pharmaceuticals Inc’s (CPIX) Risks?

    If you are a shareholder in Cumberland Pharmaceuticals Inc’s (NASDAQ:CPIX), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CPIX earnings conference call or presentation 8-Aug-17 8:30pm GMT

    Q2 2017 Cumberland Pharmaceuticals Inc Earnings Call

  • Associated Press2 months ago

    Cumberland reports 2Q loss

    On a per-share basis, the Nashville, Tennessee-based company said it had a loss of 32 cents. Losses, adjusted for pretax expenses and non-recurring costs, were 5 cents per share. The pharmaceutical company ...

  • PR Newswire2 months ago

    Cumberland Pharmaceutical Reports Double Digit Revenue Growth For The Fourth Consecutive Quarter

    - Revenues Grew 17% Over the Prior Year Period - New Co-Promotion Agreement for Kristalose® added NASHVILLE, Tenn. , Aug. 8, 2017 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty ...

  • ACCESSWIRE2 months ago

    Investor Network: Cumberland Pharmaceuticals Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2017 / Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ) will be discussing their earnings results in their Q2 Earnings Call to be held on Tuesday, August 8, 2017 at ...

  • PR Newswire3 months ago

    Cumberland Pharmaceuticals To Announce Second Quarter 2017 Financial Results

    NASHVILLE, Tenn. , Aug. 1, 2017 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release second quarter 2017 financial results after the market closes on Tuesday, ...

  • PR Newswire3 months ago

    Cumberland Pharmaceuticals Begin U.S. Shipments Of Dexrazoxane For Oncology Patient Support

    NASHVILLE, Tenn., July 31, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX), a specialty pharmaceutical company focused on the development of innovative treatments for underserved patient populations, will begin distributing dexrazoxane, sold under the brand name Totect®, to U.S. wholesalers today. Totect is an FDA-approved emergency oncology intervention indicated to treat the toxic effects of anthracycline chemotherapy in case of extravasation. Extravasation occurs when an injected medicine escapes from the blood vessels and circulates into surrounding tissues in the body, causing severe damage and serious complications.

  • Capital Cube3 months ago

    ETFs with exposure to Cumberland Pharmaceuticals, Inc. : July 12, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cumberland Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to CPIX-US. Comparing the performance and risk of Cumberland Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube5 months ago

    ETFs with exposure to Cumberland Pharmaceuticals, Inc. : May 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cumberland Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to CPIX-US. Comparing the performance and risk of Cumberland Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Cumberland Pharmaceuticals, Inc. :CPIX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
    Capital Cube5 months ago

    Cumberland Pharmaceuticals, Inc. :CPIX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017

    Categories: Yahoo FinanceGet free summary analysis Cumberland Pharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Cumberland Pharmaceuticals, Inc. – Ironwood Pharmaceuticals, Inc. Class A, Pernix Therapeutics Holdings, Inc., DURECT Corporation, Mylan N.V., Merck & Co., Inc., Akorn, Inc., Pfizer Inc. and Sucampo Pharmaceuticals, ... Read more (Read more...)

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of CPIX earnings conference call or presentation 15-May-17 8:30pm GMT

    Q1 2017 Cumberland Pharmaceuticals Inc Earnings Call

  • Associated Press5 months ago

    Cumberland reports 1Q loss

    The Nashville, Tennessee-based company said it had a loss of 8 cents per share. Earnings, adjusted for non-recurring costs and stock option expense, came to 2 cents per share. The pharmaceutical company ...

  • PR Newswire5 months ago

    Cumberland Pharmaceuticals Reports Revenue Growth Of 25% In First Quarter 2017

    NASHVILLE, Tenn., May 15, 2017 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced ...

  • Accesswire5 months ago

    Investor Network: Cumberland Pharmaceuticals Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 15, 2017 / Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ) will be discussing their earnings results in their Q1 Earnings Call to be held May 15, 2017 at 4:30 PM Eastern ...

  • PR Newswire5 months ago

    Cumberland Pharmaceuticals to Announce First Quarter 2017 Financial Results

    NASHVILLE, Tenn., May 8, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX) announced today that it will release first quarter 2017 financial results after the market closes on Monday, May 15, 2017.  A conference call and live Internet webcast will be held on Monday, May 15, 2017, at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers).  A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 855-859-2056 (for U.S. callers) or 404-537-3406 (for international callers).  The Conference ID for the rebroadcast is 11376419. The live webcast and rebroadcast can be accessed via Cumberland's website at http://investor.shareholder.com/cpix/events.cfm.

  • PR Newswire6 months ago

    New Kristalose® Growth Driver Established Through Co-Promotion Agreement

    NASHVILLE, Tenn., April 26, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals (CPIX), a U.S. specialty pharmaceutical company and Poly Pharmaceuticals Inc., a privately-held U.S. specialty pharmaceutical company, have entered into a co-promotion partnership for Kristalose® within the United States. Poly's sales force will more than double the number of nationwide physicians called upon in support of the product.

  • PR Newswire7 months ago

    Caldolor® Demonstrates Significant Post Surgical Pain Reduction and Decrease in Opioid Use

    NASHVILLE, Tenn., March 27, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX) today announced the publication of a trial providing evidence that using Caldolor in multimodal pain control strategies improves postoperative pain control and reduces opioid use in patients undergoing transsphenoidal surgery. The trial was conducted at the Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center in Phoenix, Arizona, and was published in the Journal of Neurosurgery, March 2017. "The United States is in the midst of an epidemic of excessive opioid use, misuse, and abuse to control chronic pain," said AJ Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals.

  • Accesswire7 months ago

    INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Cumberland Pharmaceuticals Inc.

    NEW YORK, NY / ACCESSWIRE / March 22, 2017 / Levi & Korsinsky announces it has commenced an investigation Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) concerning possible breaches of fiduciary duty. ...

  • Cumberland Pharmaceuticals, Inc. :CPIX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
    Capital Cube7 months ago

    Cumberland Pharmaceuticals, Inc. :CPIX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017

    Categories: Yahoo Finance Get free summary analysis Cumberland Pharmaceuticals, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Cumberland Pharmaceuticals, Inc. – Ironwood Pharmaceuticals, Inc. Class A, DURECT Corporation, Mylan N.V., Merck & Co., Inc., Akorn, Inc., Pfizer Inc. and Sucampo Pharmaceuticals, Inc. Class A (IRWD-US, ... Read more (Read more...)

  • Business Wire7 months ago

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Cumberland Pharmaceuticals Inc.

    Levi & Korsinsky announces it has commenced an investigation Cumberland Pharmaceuticals Inc. concerning possible breaches of fiduciary duty. To obtain additional

  • Cumberland Pharmaceuticals, Inc. :CPIX-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017
    Capital Cube7 months ago

    Cumberland Pharmaceuticals, Inc. :CPIX-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017

    Categories: Yahoo Finance Get free summary analysis Cumberland Pharmaceuticals, Inc. reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of Cumberland Pharmaceuticals, Inc. – Ironwood Pharmaceuticals, Inc. Class A, Akorn, Inc., Merck & Co., Inc., Mylan N.V., Sucampo Pharmaceuticals, Inc. Class A and Pfizer Inc. (IRWD-US, AKRX-US, MRK-US, ... Read more (Read more...)

  • Thomson Reuters StreetEvents7 months ago

    Edited Transcript of CPIX earnings conference call or presentation 7-Mar-17 9:30pm GMT

    Q4 2016 Cumberland Pharmaceuticals Inc Earnings Call